CDX
SU-DHL-6
Tumor indication
Lymphoma
Tumor subtype
DLBCL (GCB)
Description
SU-DHL-6 (Lymphoma CDX Model)
The SU-DHL-6 cell line was derived from a diffuse large B-cell lymphoma (DLBCL). It represents aggressive B-cell malignancies. SU-DHL-6 is commonly used in hematology research and therapeutic testing. Its consistent biology supports translational lymphoma studies.
Key Features:
- Derived from diffuse large B-cell lymphoma.
- Aggressive B-cell lymphoma line.
- Suspension culture growth.
- Tumorigenic in xenografts.
Applications:
SU-DHL-6 supports evaluation of targeted therapies for DLBCL. It is used in biomarker development and signaling pathway studies. Researchers employ it in resistance and drug screening research. Its reproducibility makes it valuable for translational pipelines.
Details
- Tumor indication
- Lymphoma
- Tumor subtype
- DLBCL (GCB)
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.